Literature DB >> 19255724

No association of (-131C-->G) variant of CHI3L1 gene with risk of glioblastoma and prognosis.

Blandine Boisselier1, Yannick Marie, Soufiane El Hallani, Gentian Kaloshi, Anton Iershov, Vadym Kavsan, Dimitri Psimaras, Joëlle Thillet, Khe Hoang-Xuan, Jean-Yves Delattre, Marc Sanson.   

Abstract

Expression of CHI3L1 (YKL-40) has been correlated with prognosis of glioblastoma. The variant allele (-131C-->G) of CHI3L1 promoter results in a lower transcription of CHI3L1. Therefore, we tested the hypothesis that the G variant could protect against the risk of gliomas or have a favorable prognostic impact. DNA from 296 glioblastoma patients and 190 controls were genotyped on the -131 allele. Tumor RNA was obtained from 108 patients for CHI3L1 transcript quantification. Neither genotype nor allele distribution differed between patients and controls. There was no significant difference in survival between the CC, CG, and GG patients despite the few GG patients tended to have a longer survival. There was no correlation between genotype and CHI3L1 expression in tumor samples. Taken together our data suggest that the variant allele (-131C-->G) of CHI3L1 promoter has no significant impact on survival and is not a prognostic factor for glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255724     DOI: 10.1007/s11060-009-9817-4

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

Review 1.  Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.

Authors:  Julia S Johansen
Journal:  Dan Med Bull       Date:  2006-05

2.  gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells.

Authors:  Kimi C Nishikawa; Albert J T Millis
Journal:  Exp Cell Res       Date:  2003-07-01       Impact factor: 3.905

3.  Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells.

Authors:  Nanna Junker; Julia S Johansen; Lasse T Hansen; Eva L Lund; Paul E G Kristjansen
Journal:  Cancer Sci       Date:  2005-03       Impact factor: 6.716

4.  YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.

Authors:  Catherine L Nutt; Rebecca A Betensky; Melissa A Brower; Tracy T Batchelor; David N Louis; Anat O Stemmer-Rachamimov
Journal:  Clin Cancer Res       Date:  2005-03-15       Impact factor: 12.531

5.  YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

Authors:  Adília Hormigo; Bin Gu; Sasan Karimi; Elyn Riedel; Katherine S Panageas; Mark A Edgar; Meena K Tanwar; Jasti S Rao; Martin Fleisher; Lisa M DeAngelis; Eric C Holland
Journal:  Clin Cancer Res       Date:  2006-10-01       Impact factor: 12.531

6.  Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia.

Authors:  Xinzhi Zhao; Ruqi Tang; Bo Gao; Yongyong Shi; Jian Zhou; Shengzhen Guo; Jing Zhang; Yabing Wang; Wei Tang; Junwei Meng; Sheng Li; Hongsheng Wang; Gang Ma; Chuwen Lin; Yue Xiao; Guoyin Feng; Zhiguang Lin; Shaomin Zhu; Yangling Xing; Hong Sang; David St Clair; Lin He
Journal:  Am J Hum Genet       Date:  2006-11-13       Impact factor: 11.025

7.  Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival.

Authors:  Margaret Wrensch; John K Wiencke; Joe Wiemels; Rei Miike; Joe Patoka; Michelle Moghadassi; Alex McMillan; Karl T Kelsey; Kenneth Aldape; Kathleen R Lamborn; Andrew T Parsa; Jennette D Sison; Michael D Prados
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

8.  Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function.

Authors:  Carole Ober; Zheng Tan; Ying Sun; Jennifer D Possick; Lin Pan; Raluca Nicolae; Sadie Radford; Rodney R Parry; Andrea Heinzmann; Klaus A Deichmann; Lucille A Lester; James E Gern; Robert F Lemanske; Dan L Nicolae; Jack A Elias; Geoffrey L Chupp
Journal:  N Engl J Med       Date:  2008-04-09       Impact factor: 91.245

9.  HC gp-39 gene is upregulated in glioblastomas.

Authors:  Katherina Shostak; Vyacheslav Labunskyy; Vladimir Dmitrenko; Tatiana Malisheva; Michail Shamayev; Vladimir Rozumenko; Yuriy Zozulya; Günter Zehetner; Vadym Kavsan
Journal:  Cancer Lett       Date:  2003-08-20       Impact factor: 8.679

10.  Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.

Authors:  Meena K Tanwar; Mark R Gilbert; Eric C Holland
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

View more
  9 in total

Review 1.  Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk.

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal
Journal:  Mediators Inflamm       Date:  2018-10-25       Impact factor: 4.711

2.  Gene Encoding Chitinase 3-Like 1 Protein (CHI3L1) is a Putative Oncogene.

Authors:  Vadym M Kavsan; Vladimir P Baklaushev; Olena V Balynska; Anton V Iershov; Pavlo O Areshkov; Gaukhar M Yusubalieva; Nadezhda Ph Grinenko; Ilya V Victorov; Vadym I Rymar; Marc Sanson; Vladimir P Chekhonin
Journal:  Int J Biomed Sci       Date:  2011-09

3.  Are SMAD7 rs4939827 and CHI3L1 rs4950928 polymorphisms associated with colorectal cancer in Egyptian patients?

Authors:  Amal Ahmed Abd El-Fattah; Nermin Abdel Hamid Sadik; Olfat Gamil Shaker; Amal Mohamed Kamal
Journal:  Tumour Biol       Date:  2016-01-16

4.  Functional variant of CHI3L1 gene is associated with neck metastasis in oral cancer.

Authors:  Chun-Wen Su; Mu-Kuan Chen; Wei-Chen Hung; Shun-Fa Yang; Chun-Yi Chuang; Chiao-Wen Lin
Journal:  Clin Oral Investig       Date:  2018-10-19       Impact factor: 3.573

5.  Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40.

Authors:  Camilla Bjørnbak Holst; Ib Jarle Christensen; Jane Skjøth-Rasmussen; Petra Hamerlik; Hans Skovgaard Poulsen; Julia Sidenius Johansen
Journal:  Front Oncol       Date:  2020-04-17       Impact factor: 6.244

6.  YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?

Authors:  Nicolai A Schultz; Julia S Johansen
Journal:  Cancers (Basel)       Date:  2010-07-12       Impact factor: 6.639

Review 7.  Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.

Authors:  Fabio M Iwamoto; Adília Hormigo
Journal:  Front Oncol       Date:  2014-04-28       Impact factor: 6.244

8.  High CHI3L1 expression is associated with glioma patient survival.

Authors:  Giedrius Steponaitis; Daina Skiriutė; Arunas Kazlauskas; Ieva Golubickaitė; Rytis Stakaitis; Arimantas Tamašauskas; Paulina Vaitkienė
Journal:  Diagn Pathol       Date:  2016-04-27       Impact factor: 2.644

9.  DNA Methylation-based Diagnostic and Prognostic Biomarkers for Glioblastoma.

Authors:  Yunliang Tang; Cheng Qing; Jiao Wang; Zhenguo Zeng
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.